Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GlycoMimetics Receives $15M Pfizer Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

GlycoMimetics Receives $15M Pfizer Milestone

Rivipansel moves to Phase III development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GlycoMimetics, Inc. has received a $15 million payment from Pfizer under the companies’ collaboration for the development of rivipansel (GMI-1070). Pfizer plans to initiate a Phase III trial of rivipansel, which will trigger an additional $20 million milestone payment to GlycoMimetics upon dosing of the first patient in the trial.
 
“Moving into Phase III will be a significant step forward in our effort to potentially address the unmet needs of individuals with sickle cell disease. With the commitment of our collaborator, Pfizer, we hope this will enable us to bring to patients, caregivers and physicians an important new medication for treatment of vaso-occlusive crisis or VOC of sickle cell disease,” said Rachel King, chief executive officer, GlycoMimetics.
 
The companies entered the collaboration and exclusive license agreement with for rivipansel in October 2011. The companies are currently developing rivipansel as a potential treatment for VOC of sickle cell disease.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics